Julien Nono-Womdim's Top Picks for Feb. 10, 2026 [BNN Bloomberg (Canada)]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: BNN Bloomberg
Focus: U.S. equities MARKET OUTLOOK: A world beyond the magnificent 7. U.S. equity markets continue to march higher and at Goodreid our view remains unchanged. We believe that the cyclical bull market that started in October 2022 is still underway and returns in 2026 should be above average, supported by two factors. First, the earnings backdrop is strong, and we are seeing a broadening in market participation with the equal-weight S&P 500 as well as small caps showing clear market leadership. Secondly, while the current U.S. administration has created a great deal of strategic uncertainty, policy will likely be positive for asset prices: the One Big Beautiful Bill will drive incremental consumption among low-tier consumers while tariffs have been a forcing mechanism for capital investment in the U.S. Sign up for the Market Call Top Picks newsletter at bnnbloomberg.ca/subscribe TOP PICKS: Citigroup (C NYSE) Citigroup has a turnaround with ongoing potential. Under
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction [Seeking Alpha]Seeking Alpha
- Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers SymposiumBusiness Wire
- KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS =1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line TreatmentBusiness Wire
- Merck: The Spike Doesn't Make It Overvalued [Seeking Alpha]Seeking Alpha
- Merck: A Buy For 2026, But The Clock Is Still Ticking [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/10/26 - Form 144
- 2/10/26 - Form 4
- 2/9/26 - Form 144
- MRK's page on the SEC website